Skip to content

Arcus Biosciences, Inc.

RCUS· NYSECore metricsCIK 1724521

Pharmaceutical preparations551 peers

Last sale
Nov 12, 2026 · -5.51%
Market cap
$2.56B
143.99M shares
Filings
609
$3.00M
Q3 2026−4.3% FY25 yoy
-$128.00M
Q3 2026N/M FY25 yoy
-$131.00M
Q3 2026N/M FY25 yoy
-$345.00M
Q3 2026derivedN/M FY25 yoy
-$1.00
Q3 2026N/M FY25 yoy
$151.00M
Q3 2026+48.0% FY25 yoy
$2.56B
—
9.5×
7.1×
-18.22%
—

Twelve months to Sep 30, 2026 · derived

Price

$17.7712.40%$2.52past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$247.00MFY 2025
$383.00M0FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$247,000,000reported
FY 20242024-12-31$258,000,000reported
FY 20232023-12-31$117,000,000 revisedreported
FY 20222022-12-31$38,000,000 revisedreported
FY 20212021-12-31$383,000,000reported
FY 20202020-12-31$78,000,000 revisedreported
FY 20192019-12-31$15,000,000reported
FY 20182018-12-31$8,353,000reported
FY 20172017-12-31$1,413,000reported

Capital returns

Dividends and buybacks · FY2018 to FY2019
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2019—$94.00K$94.00K—45.97M sh+3.2%—
FY2018—$0.00$0.00—44.53M sh+988.6%—

Segments

Products
Revenue by Products, FY2018 to FY2023FY2018Other · FY2018 · $16.71MFY2019Other Collaboration Revenue · FY2019 · $7.00MOther · FY2019 · $37.00MFY2020License and Development Services Revenue · FY2020 · $55.00MOther Collaboration Revenue · FY2020 · $23.00MAccess rights · FY2020 · $16.00MAccess rights · FY2020 · $7.00MOther · FY2020 · $217.03MFY2021License and Development Services Revenue · FY2021 · $345.00MLicense and R&D services · FY2021 · $1.00MOther Collaboration Revenue · FY2021 · $38.00MAccess rights · FY2021 · $31.00MAccess rights · FY2021 · $7.00MLicense to domvanalimab · FY2021 · $329.00MOther · FY2021 · $711.72MFY2022License and Development Services Revenue · FY2022 · $74.00MLicense and R&D services · FY2022 · $74.00MOther Collaboration Revenue · FY2022 · $38.00MAccess rights · FY2022 · $33.00MAccess rights · FY2022 · $5.00MFY2023License and Development Services Revenue · FY2023 · $80.00MLicense and R&D services · FY2023 · $79.00MOther Collaboration Revenue · FY2023 · $37.00MAccess rights · FY2023 · $33.00MR&D services · FY2023 · $5.00M
LineFY2023ShareChange
License and Development Services Revenue$80.00M216%+8.1%
License and R&D services$79.00M214%+6.8%
Other Collaboration Revenue$37.00M100%−2.6%
Access rights$33.00M89%±0.0%
R&D services$5.00M14%—
Access rights$0.00—−100.0%
License to domvanalimab$0.00——
Other———
Total$37.00M

From the 10-K filed Feb 21, 2024RCUS

Pharmaceutical preparations

Arcus Biosciences, Inc. is the 77th largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Arcus Biosciences, Inc. · CIK 1724521 · Engraved from SEC EDGAR